Home Featured Page 85

Featured

Latest

Momentum Amidst Tumult: The FDA Reshuffle, Approval Timelines, and the Compass-Usona Race

Field Notes #1: Psychiatrists, Regulators, Ibogaine, and the Race for Psilocybin Approval

At the Federal Psychedelic Medicine Summit, the Mood Was Urgent, Practical, and Increasingly Coordinated

Bit Yaden on Preparing the Next Generation of Psychiatrists for a Psychedelic Future

“If I can’t change my views based on evidence, then why do science at all?” Nora Volkow on Psychedelics

Algernon Pharmaceuticals Announces Grant of U.S. Patent for Repirinast in NAFLD...

PharmaTher Submits Priority Original Abbreviated New Drug Application for KETARX™ (Ketamine)...

COMPASS Pathways announces publication of first study evaluating potential of AI...

Perfect Your Craft and Deliver Your Best Results with Homecoming

PT438 – The Psychedelic Medicine Association and Managing Medical Risk in...

Optimi Health Announces Second Tranche of CAD $1,000,000 Secured for Debt...

BetterLife Highlights BETR-001 Article in Technology Networks Drug Discovery and Announces...

California Psychedelic Decriminalisation Bill Clears Appropriations Committee with Amendments

PT437 – Exploring Psychedelic Therapies: Iboga, CBD, and Cannabis Paired With...

Natural Medicine Advisory Bulletin #3: August 2023

EDITOR PICKS

Momentum Amidst Tumult: The FDA Reshuffle, Approval Timelines, and the Compass-Usona...

Field Notes #1: Psychiatrists, Regulators, Ibogaine, and the Race for Psilocybin...

At the Federal Psychedelic Medicine Summit, the Mood Was Urgent, Practical,...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.